Exicure Granted Broad U.S. Patent #11866700 Today For "Liposomal Nucleic Acid Constructs Presenting Antisense Oligonucleotides For Knockdown Of Interleukin 17 Mrna (For Inflammation From Cancer, Obesity, Diabetes, Alzheimer's)"
Portfolio Pulse from Benzinga Newsdesk
Exicure has been granted a broad U.S. patent (#11866700) for its technology involving liposomal nucleic acid constructs that present antisense oligonucleotides for the knockdown of interleukin 17 mRNA. This technology has potential applications in treating inflammation associated with cancer, obesity, diabetes, and Alzheimer's disease.
January 09, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exicure's new U.S. patent for antisense oligonucleotides technology could enhance its intellectual property portfolio and potentially lead to new treatments for inflammatory conditions.
The granting of a broad U.S. patent to Exicure for a potentially groundbreaking technology is likely to be viewed positively by investors and could lead to increased investor confidence in the company's research and development capabilities. This patent could protect Exicure's technology, potentially leading to exclusive market rights for treatments derived from it, which may have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100